ArticleEpileptic disorders : international epilepsy journal with videotape2026
Evaluation of serum irisin and meteorin-like (METRNL) levels in people with drug-resistant and drug-responsive temporal lobe epilepsy.
Article in Epileptic disorders : international epilepsy journal with videotape, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTemporal lobe epilepsy (TLE) is associated with significant comorbidities, including cognitive decline and psychiatric disorders. Myokines, such as irisin and meteorin-like (METRNL) hormone, are secreted during physical activity and possess neuroprotective and anti-inflammatory properties. This study aimed to evaluate serum irisin and METRNL concentrations in people with TLE (drug-resistant and drug-responsive) compared to healthy controls and to analyze their correlation with depression, anxiety, cognitive function, and physical activity. MATERIALS AND
methodsThis cross-sectional study included adult participants divided into three groups: drug-resistant TLE, drug-responsive TLE, and healthy controls. Serum irisin and METRNL levels were quantified using ELISA. Neuropsychological status was assessed using the Beck Depression Inventory (BDI), Spielberger State-Trait Anxiety Inventory (STAI), and Mini-Mental State Examination (MMSE). Physical activity was evaluated using the International Physical Activity Questionnaire (IPAQ).
resultsSerum METRNL levels were significantly lower in both the drug-resistant and drug-responsive TLE groups compared to the control group (p = .001). Multivariable regression analysis confirmed that epilepsy status was independently associated with lower METRNL levels (p = .039). Conversely, serum irisin levels did not differ significantly among the groups (p = .124). Participants with TLE exhibited significantly lower physical activity and MMSE scores compared to controls. Additionally, the drug-resistant TLE group showed significantly higher depression and state anxiety scores. A positive correlation was observed between physical activity levels and serum METRNL concentrations.
conclusionSerum METRNL levels are significantly reduced in people with TLE regardless of drug resistance, whereas irisin levels remain unchanged. The reduction in METRNL may reflect underlying neuroinflammatory or metabolic dysfunctions associated with epilepsy. Given the association between physical activity and METRNL, lifestyle interventions may offer therapeutic potential. METRNL warrants further investigation as a candidate biomarker for TLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.